Loading...

SQZ Biotechnologies Company

SQZ•NYSE
Healthcare
Biotechnology
$0.43
$0.16(61.11%)

SQZ Biotechnologies Company (SQZ) Stock Overview

Explore SQZ Biotechnologies Company’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.2/100

Key Financials

Market Cap12.8M
P/E Ratio-0.16
EPS (TTM)$-2.16
ROE-0.86%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.05

SQZ Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of SQZ Biotechnologies Company (SQZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.05.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.16 and a market capitalization of 12.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for SQZStats details for SQZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for SQZAnalyst Recommendations details for SQZ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

CEO

Dr. Howard Bernstein M.D., Ph.D.

Employees

53

Headquarters

200 Arsenal Yards Boulevard, Watertown, MA

Founded

2020

Frequently Asked Questions

;